Nureca Q1 FY27: Higher Revenue, Stronger Margins, and a Manufacturing Push

Nureca opened FY27 with a quarter that reinforced the operational turnaround seen in FY26. In Q1 FY27, revenue from operations rose to ₹40.3 crore, up 18% year on year and 14% quarter on quarter. Profitability improved alongside growth. Operating profit reached ₹3.5 crore and profit after tax came in at ₹3.1 crore.

Management framed the quarter around two priorities: profitable growth and disciplined cost management. The company also reiterated a longer-term thesis. It wants to build an integrated consumer healthcare platform that combines branded products, omnichannel distribution, connected devices, and domestic manufacturing.

A quarter where profitability moved meaningfully

The company reported Q1 FY27 gross margin of 39%, broadly stable versus the prior year. What stood out was operating leverage. Operating margin improved to 8.7%, while EBITDA margin reached 12%. This was a clear step up from Q4 FY26, when the company had reported negative profitability.

A bridge shared in the presentation helps explain how profits flowed through in Q1. Operating profit of ₹3.42 crore was supported by other income of ₹1.82 crore. After finance cost of ₹0.20 crore and depreciation of ₹0.61 crore, profit before tax stood at ₹4.43 crore. Reported PAT was ₹3.1 crore.

The company also highlighted that this was its highest quarterly sales and profitability in the last 16 quarters, describing it as the strongest performance since Q4 FY 2021-22.

Business model: Brands, omnichannel distribution, and connected devices

Nureca positions itself as a branded consumer healthcare platform. The portfolio spans home healthcare and wellness categories through its brands Dr Trust and Dr Physio. The presentation also includes Trumom, which targets mother and baby care.

The product architecture is presented as seven ranges across the home health journey. These include monitoring and diagnosis at home, fitness and body tracking products, massage-led recovery products, therapy and rehabilitation devices, orthotics, mother and baby care products, and healthy home products.

Distribution remains heavily online. In Q1 FY27, 87.6% of sales were online and 12.4% were offline. The company reported online sales growth of 16% year on year and 5% quarter on quarter. Offline growth was higher off a smaller base, with revenue up 57% year on year and 14% quarter on quarter, supported by expansion of super stockists and new distributors.

A second layer of differentiation comes from connected devices and the Dr Trust 360 ecosystem. Nureca reported 2.4 million app users for Dr Trust 360. The company also stated that the platform now includes AI-powered health insights, trend detection and summaries. The presentation positions this as a way to deepen customer engagement through device-led data and personalised insights.

Manufacturing as the long-term engine

Management commentary places manufacturing at the centre of long-term strategy. The presentation highlights NTPL Mohali as the current manufacturing base, with an annual capacity of 8 lakh units and 15 CDSCO approvals.

The company disclosed that revenue from in-house manufacturing products was 26% in FY26 and increased to 27% in Q1 FY27. Categories manufactured include BP monitors, nebulizers, thermometers, massagers, heating pads, orthopaedic cushions and supports, breast pumps, vaporisers, and soft orthopaedic goods.

Beyond the existing base, the company’s timeline notes that construction has begun for a new medical device facility at Sundran, Punjab. Management stated that expanding capabilities in Punjab is intended to improve supply chain control and enable import substitution, while opening new opportunities in medical devices, healthcare consumables, and hygiene products.

This matters because it connects directly to margin stability and execution control. While the presentation does not quantify expected cost savings or returns on investment, it is explicit that domestic manufacturing is expected to strengthen supply chain resilience and broaden the addressable product set.

Corporate announcement: promoter holding change through family settlement

A separate stock exchange disclosure under SEBI SAST regulations stated that promoter Saurabh Goyal increased his shareholding and voting rights pursuant to a family settlement agreement dated June 17, 2026.

The disclosure states the transaction was an off-market inter se transfer by way of gift, with the acquisition date listed as July 2, 2026. After the transaction, Saurabh Goyal’s holding increased to 64,97,169 shares, equivalent to 68.09% of the company’s voting capital. The disclosure notes that promoter and promoter group shareholding remained unchanged in aggregate.

Outlook anchored in execution discipline

The company did not provide numeric guidance in the presentation. What it did provide was a clear qualitative stance. Management reiterated a focus on profitable growth and disciplined cost management. It also underlined that manufacturing will be central to its long-term plan, alongside scaling its connected health ecosystem.

Industry context in the presentation points to a growing market. The company cited a Frost and Sullivan based estimate for the home healthcare products market in India and neighboring countries, projecting growth from ₹3,240 crore in 2025 to ₹5,203 crore by 2030E, implying a 9.9% CAGR. The presentation also states that Nureca competes across eight categories outlined in that market sizing.

Key takeaways

Q1 FY27 showed a cleaner operating profile than prior quarters, with higher revenue and meaningfully improved margins. A strong net cash and investments position of ₹110 crore and a debt-free balance sheet provide financial flexibility.

The strategic direction is consistent across the presentation. Nureca wants to combine brands, omnichannel distribution, connected devices, and manufacturing to build a consumer healthcare platform. The near-term performance shows progress, while the longer-term manufacturing expansion in Punjab and the Dr Trust 360 ecosystem remain the main strategic levers investors will likely track through FY27.